High expression of CD47 has been shown to correlate with poor clinical outcomes in patients with hematological cancers such as non-Hodgkin lymphoma [10] or acute myeloid leukemia (AML) [14] and also in solid tumors (ovarian, glioblastoma, glioma, and others) [15] and proposed to be a clinical prognostic factor. This evidence concerns the gene CD47 and glioma.